PharmaTher's 3D Printed Medicine Plan: A New Era for ASEAN Factories

A New Chapter in Pharmaceutical Manufacturing for ASEAN Factories \\[PharmaTher Holdings](https://www.pharmather.com/), a specialty pharmaceutical company, is set to revolutionize the way drugs are produced and distributed. The company has announced an ambitious roadmap that includes the launch of its CraftMake 3D printer, which is designed to produce personalized, small-batch medications. This innovative approach not only promises to make drug production more efficient but also opens up new possibilities for factories in Thailand, Vietnam, Indonesia, and Malaysia. \\[CraftMake 3D Printer](https://www.crafthealth.com/) is a GMP-ready system developed by Singapore-based Craft Health. PharmaTher aims to place up to 50 units across North America within the next year, targeting pharmacies, telehealth providers, contract development and manufacturing organizations (CDMOs), hospitals, research facilities, and government sites. The potential for similar installations in ASEAN countries is significant, given the region's growing demand for advanced medical technologies. \\### Transforming Local Manufacturing \\[The introduction of 3D printed medicine](https://www.3dprintingindustry.com/news/pharmather-sets-3d-printed-medicine-roadmap-targeting-first-craftmake-orders-this-quarter-and-a-rare-pediatric-nda-by-2028-179462/) offers several advantages for ASEAN factories. Traditional drug production methods are optimized for large-scale, uniform batches, which can be inefficient for producing small, customized doses. 3D printing, on the other hand, allows for the economical production of patient-specific medications, making it ideal for treating rare diseases, providing emergency preparedness, and addressing the needs of pediatric patients. \\In Thailand, where the healthcare sector is rapidly modernizing, 3D printed medicine could significantly enhance the country's capacity to provide personalized treatments. Similarly, in Vietnam, where there is a growing focus on improving healthcare infrastructure, this technology could help meet the increasing demand for specialized medications. In Indonesia and Malaysia, 3D printing could support the development of localized drug production, reducing dependency on imports and enhancing national health security. \\### Opportunities for Collaboration \\PharmaTher's strategy involves both developing its own products and opening the platform to external partners. For ASEAN factories, this presents a range of opportunities, from purchasing and operating the CraftMake 3D printers to licensing formulations, white-label products, and engaging in research collaborations. The company is also exploring the use of 3D printed medicine for emergency preparedness, storing active ingredients and digital formulations that can be quickly deployed during public health crises. \\This approach aligns well with the region's efforts to build resilient healthcare systems. For example, in Malaysia, the government has been investing in advanced manufacturing technologies to improve the country's response to health emergencies. 3D printed medicine could play a crucial role in these efforts, providing a flexible and scalable solution for producing essential drugs. \\### Concrete Takeaways for Factory Buyers \\For factory buyers in ASEAN, the adoption of 3D printed medicine represents a strategic investment in the future of pharmaceutical manufacturing. By integrating this technology, factories can position themselves at the forefront of innovation, meeting the diverse and evolving needs of patients and healthcare providers. Additionally, the potential for recurring revenue from software, consumables, and service contracts makes 3D printing a financially attractive option. \\In summary, PharmaTher's 3D printed medicine roadmap offers a transformative opportunity for ASEAN factories. By embracing this technology, local manufacturers can enhance their capabilities, contribute to improved healthcare outcomes, and drive economic growth in the region. The time to act is now, as the benefits of 3D printed medicine are poised to reshape the pharmaceutical landscape in Southeast Asia.